Overview

Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 2 years and over.

Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs. Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.

Hereditary angioedema is rare, and Takhzyro was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 October 2015. Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu3151551.

Takhzyro contains the active substance lanadelumab.

Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms. The recommended dose and frequency depends on the patient’s age and bodyweight. At the beginning of treatment the dose is usually given every 2 weeks, which the doctor can reduce to once every 4 weeks if the patient remains free of attacks with the two-weekly dose.

Caregivers or patients aged 12 years and above may inject the medicine themselves after they have been properly trained.

Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema.

For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.

Patients with hereditary angioedema have high levels of a substance called ‘bradykinin’, which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in angioedema.

The active substance in Takhzyro, lanadelumab, works by attaching to and blocking an enzyme in the blood called 'kallikrein', which has several functions, including increasing levels of bradykinin. By blocking the actions of kallikrein, lanadelumab helps to prevent the swelling and related symptoms of angioedema.

Takhzyro was found to be effective in reducing the number of angioedema attacks in a main study in 126 adults and children above 12 years of age with hereditary angioedema.

Patients experienced on average 0.3 attacks per month when given Takhzyro injections every 2 weeks and 0.5 attacks when given injections every 4 weeks. This compared with 2 attacks per month for patients on placebo (a dummy treatment).

An additional study was carried out in 21 children with hereditary angioedema aged between 2 and 12 years. Treatment with Takhzyro reduced the number of angioedema attacks from on average 1.84 attacks per month to 0.08 attacks after one year of treatment.

For the full list of side effects and restrictions with Takhzyro, see the package leaflet.

The most common side effects with Takhzyro (which may affect more than 1 patient in 10) include reactions at the site of injection including erythema (redness), bruising and pain.

Takhzyro is effective in preventing angioedema attacks and the fact that it only needs to be given every 2 or 4 weeks was considered an advantage over existing treatments. Overall, the safety profile was considered acceptable.

The European Medicines Agency therefore decided that Takhzyro’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Takhzyro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Takhzyro are continuously monitored. Side effects reported with Takhzyro are carefully evaluated and any necessary action taken to protect patients.

Takhzyro received a marketing authorisation valid throughout the EU on 22 November 2018.

This overview was last updated in 10-2023.

Takhzyro : EPAR - Medicine overview

български (BG) (139.85 KB - PDF)
español (ES) (117.17 KB - PDF)
čeština (CS) (138.63 KB - PDF)
dansk (DA) (116.66 KB - PDF)
Deutsch (DE) (120.12 KB - PDF)
eesti keel (ET) (114.48 KB - PDF)
ελληνικά (EL) (140.16 KB - PDF)
français (FR) (118.79 KB - PDF)
hrvatski (HR) (138.45 KB - PDF)
italiano (IT) (116.47 KB - PDF)
latviešu valoda (LV) (147.21 KB - PDF)
lietuvių kalba (LT) (139.64 KB - PDF)
magyar (HU) (137.45 KB - PDF)
Malti (MT) (140.55 KB - PDF)
Nederlands (NL) (117.46 KB - PDF)
polski (PL) (139.65 KB - PDF)
português (PT) (118.03 KB - PDF)
română (RO) (138.26 KB - PDF)
slovenčina (SK) (159.12 KB - PDF)
slovenščina (SL) (136.81 KB - PDF)
Suomi (FI) (115 KB - PDF)
svenska (SV) (116.45 KB - PDF)

Takhzyro : EPAR - Risk-management-plan summary

Product information

Takhzyro : EPAR - Product information

български (BG) (1.78 MB - PDF)
español (ES) (1.88 MB - PDF)
čeština (CS) (2.64 MB - PDF)
dansk (DA) (2.04 MB - PDF)
Deutsch (DE) (2.07 MB - PDF)
eesti keel (ET) (2.13 MB - PDF)
ελληνικά (EL) (2.43 MB - PDF)
français (FR) (2.03 MB - PDF)
hrvatski (HR) (2.42 MB - PDF)
íslenska (IS) (2.26 MB - PDF)
italiano (IT) (1.74 MB - PDF)
latviešu valoda (LV) (2.62 MB - PDF)
lietuvių kalba (LT) (1.76 MB - PDF)
magyar (HU) (2.42 MB - PDF)
Malti (MT) (1.74 MB - PDF)
Nederlands (NL) (1.97 MB - PDF)
norsk (NO) (1.9 MB - PDF)
polski (PL) (2.55 MB - PDF)
português (PT) (1.89 MB - PDF)
română (RO) (1.74 MB - PDF)
slovenčina (SK) (2.13 MB - PDF)
slovenščina (SL) (2.15 MB - PDF)
Suomi (FI) (1.91 MB - PDF)
svenska (SV) (1.86 MB - PDF)

Latest procedure affecting product information: X/0034/G

14/12/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Takhzyro : EPAR - All authorised presentations

български (BG) (62.88 KB - PDF)
español (ES) (52.27 KB - PDF)
čeština (CS) (59.85 KB - PDF)
dansk (DA) (55.41 KB - PDF)
Deutsch (DE) (57.59 KB - PDF)
eesti keel (ET) (52.63 KB - PDF)
ελληνικά (EL) (55.32 KB - PDF)
français (FR) (56.37 KB - PDF)
hrvatski (HR) (57.2 KB - PDF)
íslenska (IS) (55.95 KB - PDF)
italiano (IT) (54.29 KB - PDF)
latviešu valoda (LV) (59.83 KB - PDF)
lietuvių kalba (LT) (59.06 KB - PDF)
magyar (HU) (57.54 KB - PDF)
Malti (MT) (57.8 KB - PDF)
Nederlands (NL) (51.48 KB - PDF)
norsk (NO) (57 KB - PDF)
polski (PL) (58.32 KB - PDF)
português (PT) (55.11 KB - PDF)
română (RO) (56 KB - PDF)
slovenčina (SK) (58.11 KB - PDF)
slovenščina (SL) (52.92 KB - PDF)
Suomi (FI) (49.52 KB - PDF)
svenska (SV) (55.5 KB - PDF)

Product details

Name of medicine
Takhzyro
Active substance
lanadelumab
International non-proprietary name (INN) or common name
lanadelumab
Therapeutic area (MeSH)
Angioedemas, Hereditary
Anatomical therapeutic chemical (ATC) code
B06AC05

Pharmacotherapeutic group

Other hematological agents

Therapeutic indication

Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.

Authorisation details

EMA product number
EMEA/H/C/004806

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
Co Dublin
D02 HW68
Ireland

Opinion adopted
18/10/2018
Marketing authorisation issued
22/11/2018
Revision
14

Assessment history

Takhzyro : EPAR - Procedural steps taken and scientific information after the authorisation

Takhzyro-H-C-4806-P46-006 : EPAR - Assessment report

Takhzyro-H-C-4806-P46-005 : EPAR - Assessment report

Takhzyro-H-C-4806-X-0034-G : EPAR - Assessment report - Extension

Takhzyro-H-C-4806-P46-004 : EPAR - Assessment report

Takhzyro-H-C-4806-P46-001.1 : EPAR - Assessment report

Takhzyro : EPAR - Public assessment report

Takhzyro: Orphan maintenance assessment report (initial authorisation)

CHMP summary of positive opinion for Takhzyro

Topics

This page was last updated on

How useful do you find this page?